Literature DB >> 7860222

Stimulation of the 92-kD type IV collagenase promoter and enzyme expression in human melanoma cells.

M A Lauricella-Lefebvre1, V Castronovo, H Sato, M Seiki, D L French, M P Merville.   

Abstract

The 92-kD type IV collagenase is a member of the metalloproteinase family which degrades type IV collagen, a major component of basement membrane and is involved in tumor invasion and metastasis. The promoter and adjacent regulatory sequences of the 92-kD type IV collagenase have been identified previously and three cis-acting elements homologous to the binding sites for AP-1, NF-KB and SP-1 proteins contributed to induction of the promoter activity by 12-O-tetradecanoylphorbol 13-acetate (TPA) and tumor necrosis factor (TNF-alpha) in HT1080 cells. To date, no direct correlation between promoter activity and expression of the 92-kD type IV collagenase has been reported in normal or cancer cells. In this study, the effects of the transcriptional stimulation of the 92-kD type IV collagenase gene on the expression of the enzyme in human A2058 melanoma cells was analyzed by zymography experiments. Quantitative immunoblots using a monoclonal antibody that recognized specifically and exclusively the 92-kD type IV collagenase, confirmed that the 92-kD gelatinase was 92-kD type IV collagenase. Stimulation of the promoter activity resulted in increased gelatinase activity in the culture medium of A2058 cells. A direct correlation between TPA- and TNF-alpha-mediated promoter stimulation of the 92-kD type IV collagenase gene and its expression was also demonstrated in the human fibrosarcoma HT1080 cells. Interleukin-1 alpha failed to induce 92-kD gene promoter activity and type IV collagenase expression in melanoma and fibrosarcoma cell lines. Our data demonstrated that TPA- and TNF-alpha-induced 92-kD type IV collagenase promoter stimulation leads to a proportional increase of enzyme expression and secretion and thus could contribute to the activation of the invasive phenotype.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7860222

Source DB:  PubMed          Journal:  Invasion Metastasis        ISSN: 0251-1789


  7 in total

1.  Transcriptional inhibition of matrix metalloproteinase 9 (MMP-9) activity by a c-fos/estrogen receptor fusion protein is mediated by the proximal AP-1 site of the MMP-9 promoter and correlates with reduced tumor cell invasion.

Authors:  D L Crowe; T N Brown
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

2.  Cytokine sensitivity of metastatic human melanoma cell lines-- simultaneous inhibition of proliferation and enhancement of gelatinase activity.

Authors:  A Ladányi; J O Nagy; A Jeney; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

3.  Antioxidants inhibit TNFalpha-induced motility and invasion of human osteosarcoma cells: possible involvement of NFkappaB activation.

Authors:  K Harimaya; K Tanaka; Y Matsumoto; H Sato; S Matsuda; Y Iwamoto
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Enhancement of lung-colonizing potential of murine tumor cell lines co-cultivated with activated macrophages.

Authors:  O Cecconi; L Calorini; A Mannini; G Mugnai; S Ruggieri
Journal:  Clin Exp Metastasis       Date:  1997-03       Impact factor: 5.150

5.  Cellular distribution of 92-kd type IV collagenase/gelatinase B in human hepatocellular carcinoma.

Authors:  K Ashida; H Nakatsukasa; T Higashi; S Ohguchi; N Hino; K Nouso; Y Urabe; K Yoshida; N Kinugasa; T Tsuji
Journal:  Am J Pathol       Date:  1996-12       Impact factor: 4.307

6.  Combined effect of dehydroxymethylepoxyquinomicin and gemcitabine in a mouse model of liver metastasis of pancreatic cancer.

Authors:  Keiichi Suzuki; Koichi Aiura; Sachiko Matsuda; Osamu Itano; Osamu Takeuchi; Kazuo Umezawa; Yuko Kitagawa
Journal:  Clin Exp Metastasis       Date:  2012-10-31       Impact factor: 5.150

7.  Melatonin inhibits TPA-induced oral cancer cell migration by suppressing matrix metalloproteinase-9 activation through the histone acetylation.

Authors:  Chia-Ming Yeh; Chiao-Wen Lin; Jia-Sin Yang; Wei-En Yang; Shih-Chi Su; Shun-Fa Yang
Journal:  Oncotarget       Date:  2016-04-19
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.